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Abstract The impact of cyclosporine A (CsA) therapy in
patients with steroid-dependent nephrotic-syndrome
(SDNS) on long-term renal function is controversial. Data
beyond 5 years are rare. Long-term renal function was
evaluated in children with SDNS with and without CsA
therapy, especially beyond 5 years. Twenty children were
treated with CsA (study group) for a mean of 5.4±2.2 years
(ten patients for 5–11 years). Glomerular filtration rate
(GFR) was calculated before and after 3 and 12 months
and at latest follow-up of therapy. Fifteen children with
cyclophosphamide-treated SDNS without CsA served as
controls. In the study group, GFR decreased within
12 months from 136±19 to 120±31, to 114±14 ml/min
per 1.73 m
2 at latest follow-up (p<0.0001). Patients with
CsA>5 years had a GFR of 111±14 ml/min per 1.73 m
2 at
latest follow-up without a GFR below 90 ml/min per
1.73 m
2. No CsA toxicity was found in biopsies. In the
control group, GFR dropped within 3 months, from 137±
27 to 130±24, to 126±19 ml/min per 1.73 m
2 at latest
follow-up (p=0.1). Patients with and without nephrotoxic
CsA therapy showed a drop in GFR. In CsA-treated
patients, GFR was about 12% lower at latest follow-up
compared with patients without nephrotoxic therapy but
always remained within normal range. CsA seems to be
safe, even in long-term treatment for more than 5 years.
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Abbreviations
SDNS steroid-dependent nephrotic syndrome
IRNS infrequent relapsing nephrotic syndrome
FRNS frequent relapsing nephrotic syndrome
SRNS steroid-resistant nephrotic syndrome
SSNS steroid-sensitive nephrotic syndrome
FSGS focal segmental glomerulosclerosis
MCNS minimal-change nephrotic syndrome
CsA cyclosporine A
CP cyclophosphamide
GFR glomerular filtration rate
Introduction
Minimal-change nephrotic syndrome (MCNS) in children is
characterised by steroid responsiveness, subsequent relapses
and a benign prognosis concerning renal function [1].
Patients with steroid-dependent nephrotic syndrome (SDNS)
and frequent relapsing nephrotic syndrome (FRNS) with
steroid-toxic side effects are recommended for treatment with
cyclophosphamide (CP). The overall rate of cumulative
sustained remission after therapy with CP, however, was
only 24% after 10 years [2]. The efficacy of cyclosporine A
(CsA) in the treatment of steroid-sensitive nephrotic syn-
drome (SSNS) has been well demonstrated [3–8]. Early
withdraw of CsA leads to relapses of the SDNS. So patients
remain dependent on CsA for years. CsA was identified as
being nephrotoxic, inducing tubulointerstitial fibrosis [9],
vasoconstriction leading to reduced renal plasma flow and
glomerular filtration rate (GFR) [10]. The potential risk of
long-term CsA therapy to induce chronic renal failure in
patients with MCNS has been discussed controversially.
Seikaly et al. [11] found no drop in GFR but a histological
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e-mail: annett-birgitta.kranz@uk-essen.deprogression of tubulointerstitial lesions in patients treated
with CsA in comparison with those without CsA. Hulton et
al. [5, 12] demonstrated a significant reduction of GFR
within the first 3 months after introduction of CsA.
Thereafter, the GFR remained stable. In contrast, Inoue et
al. [6] could not detect a significant impairment of renal
function in patients with CsA therapy. The interpretation of
several studies focussing on the impact of CsA therapy on
long-term renal function is limited and controversial.
1. Most authors investigate the influence of CsA on renal
function in nephrotic children with different histologic
entities, not considering their different risk to progress
to chronic renal failure. Thus Niaudet et al., Habib and
Niaudet, and Gregory et al. [7, 13, 14] did not
differentiate between MCNS and focal segmental
glomerulosclerosis (FSGS) in their studies evaluating
long-term renal function in nephrotic children with CsA
therapy.
2. The physiological drop in GFR after temporary hyper-
filtration during a relapse often has been neglected.
Relapse-associated hypoproteinemia and hypoalbumi-
naemia lead to oedema and increased GFR [15]. Hulton
et al. [12] considered that concomitant therapy with
steroids could contribute to an increase of GFR due to
the mineralocorticoid effect. Consequently, steroid ces-
sation could lead to a physiological drop in GFR.
3. Several studies claim to address the long-term effect of
CsA therapy on renal function, but actually, many of
them do not extend more than 2–3 years [5, 6, 7, 12,
16], depicting the short-term effect of CsA on renal
function.
4. No study evaluated an additional control group without
nephrotoxic therapy to demonstrate the physiological
development of GFR in patients with SDNS.
In this study, we focus on the long-term renal function in
20 children with biopsy-proven MCNS treated with CsA
for a mean of 5.36±2.2 (range 2–11) years. The develop-
ment of GFR in these patients is compared with a control
group with SDNS without CsA therapy.
Patients and methods
Between 1993 and 2004, 20 children (eight girls and 12
boys) with biopsy-proven MCNS were treated with CsA for
a mean of 5.4±2.2 (median 5.0, range 2.1–11.0) years.
Patients only qualified for this retrospective analysis after a
minimum CsA therapy duration of 2 years. The definitions
and criteria for NS, remission, relapse and steroid depen-
dency were those used by the International Study of Kidney
Disease in Children (ISKDC) and the Arbeitsgemeinschaft
Pädiatrische Nephrolgie (APN) [17, 18].
All patients had SDNS and were treated with cyclophos-
phamide (CP) prior to CsA without achieving sustained
remission. CsA treatment was started with a dosage of 100–
150 mg/m
2 per body surface area (BSA) in two divided
doses. CsA dose was adjusted to a target blood level of 80–
120 ng/ml. Side effects such as hypertension, hypertrichosis
and gingival hyperplasia were not consistently documented
and could not be considered in this study. Renal function
(GFR) was calculated by the Schwartz formula ([19], κ-
factor 0.55) before and after 3 and 12 months and at the
latest follow-up of CsA therapy. Renal biopsy under CsA
therapy was performed in five patients after 4.9–7.0 years.
All patients starting CsA therapy were still on a standard
relapse treatment with prednisone (40 mg/m
2 every 48 h)
that was discontinued after 4 weeks. At the reviews after 3
and 12 months and latest follow-up, all patients were in
remission and had no steroid therapy.
In the control group, 15 children (seven girls, eight boys)
with SDNS treated with CP were evaluated for long-term
renal function. GFR was calculated before and after therapy
with CP and at the latest follow-up (mean 4.9±3.4 years).
According to APN recommendations, these patients were
treated with CP with 2 mg/kg body weight for 12 weeks
[18, 20]. As concomitant medication, all patients in the
control group received prednisone 60 mg/m
2 every 48 h
tapered to 10 mg/m
2 every 48 h and discontinued when CP
was stopped. At latest follow-up, all patients were in
remission without further steroid therapy.
Statistical analysis
Statistical analysis was performed employing SPSS 12.0 for
windows. Data were expressed as mean ± standard
deviation. Student’s t test was performed, and a p value
<0.05 was regarded as significant.
Results
Twenty paediatric patients with SDNS were treated with
CsA due to failing CP therapy for a mean of 5.4±2.2
(median 5.0, range 2.1–11.0) years. The mean starting
dosage was 130±32 mg/m
2 BSA per day. The mean CsA
dosage after 12 months was 126±26 mg/m
2 BSA per day,
with a trough level of 99±27 ng/ml. The mean age at the
beginning of CsA therapy was 8.4±3.0 (median 8.6, range
3.1–14.2) years. GFR calculated at the beginning, at months
3 and 12 and at the latest follow-up of CsA treatment was
136±19 (median 136), 130±20 (median 135), 120±31
(median 113) and 114±14 (median 114) ml/min per
1.73 m
2,r e s p e c t i v e l y( T a b l e1 and Fig. 1). Unfortunately,
data of only 12 patients were available for the calculation of
GFR at month 3. The decline in GFR from the beginning to
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p=0.025 and p<0.0001, respectively (Fig. 2). The drop in
GFR within the first 12 months was 11.8% and during the
whole follow-up 14.9%. Three patients reestablished their
GFR after cessation of CsA. No patient had a GFR below
90 ml/min per 1.73 m
2, and 17 patients had a GFR above
105 ml/min per 1.73 m
2 at latest follow-up. CsA trough level
at latest follow-up was 85±62 ng/ml; mean CsA dosage
was 105±34 mg/m
2 BSA per day.
CsA was effective in 19 of 20 patients, leading to long-
term remission or reduction of relapses to an infrequent
relapsing NS (IRNS). Chlorambucil was introduced in one
patient due to frequent relapses after CsA cessation. In three
patients, arterial hypertension was treated; in one patient,
antihypertensive therapy could be stopped after CsA
cessation. Ten patients were treated with CsA for more
than 5 (median 6.5, mean 7.0±1.8, range 5.0–11.0) years.
GFR at latest follow-up was 111±14 (median 109, range
90–132) ml/min per 1.73 m
2. Five patients underwent renal
biopsy after 5.1–7.3 years after CsA therapy had been
started before they were transferred to adult nephrologists.
CsA-associated nephrotoxicity was not reported by an
experienced renal pathologist (Prof. U. Helmchen, Hamburg,
Germany).CsAwas stoppedinninepatients(meanage 13.1±
2.5years)aftera meanof4.9±1.9(median4.4,range2.3–9.0)
years due to long-term sustained remission in all but one
patient.GFRremainednormalafterCsAcessation,with120±
25 (median 116) and 123±10 (median 125, range 105.18–
134.98) ml/min per 1.73 m
2 at time of therapy cessation and
at latest follow-up, respectively.
The control group consisted of 15 patients with SDNS
who were treated with CP at a mean age of 6.0±3.2 (median
4.6) years. At the start of CP, GFR was 138±28 (median
132) ml/min per 1.73 m
2. After 3 months, GFR dropped to
130±25 ml (median 131) ml/min per 1.73 m
2 (p=0.3).
GFR at latest follow-up (mean follow-up 4.9±3.4 years)
was 126±20 (median 125) ml/min per 1.73 m
2 (p=0.1,
Figs. 3 and 4). This drop was in the order of 8% but not
statistically significant.
Table 1 summarises the development of GFR in both
patient groups, starting with the GFR before CP therapy.
Patients of both groups had an initial decline in GFR during
CP therapy.
Discussion
Histologically, the nephrotoxic effect of CsA has been
defined by Mihatch et al. [9]: most frequent lesions
attributable to CsA are tubular atrophy, interstitial fibrosis
Fig. 1 Development of the glomerular filtration rate (GFR) of all
patients on cyclosporin A (CsA) therapy (n=20)
Table 1 Patient characteristics
[mean ± standard deviation
(SD)] and renal function
calculated by glomerular
filtration rate (GFR in ml/min
per 1.73 m
2; mean ± SD) in
patients with cyclosporine A
(CsA, study group) and with
cyclophosphamide (CP, control
group)
MCNS minimal-change
nephrotic syndrome, GFR
glomerular filtration rate
Study group n=20 Control group n=15
Age at start of MCNS (years) 4.4±2.2 4.0±2.9
Age at start of CP (years) 5.7±2.2 6.0±3.2
Age at start of CsA (years) 8.4±3.0 –
CsA trough level at month
12 (ng/ml)
98.8±26.9 –
Follow-up time (years) 5.4±2.2 4.9±3.4
GFR at start of CP 138.7±24.6 p=0.4 137.7±27.6 p=0.3
Median 132 Median 131.6
Range 119–181 Range 95–196
GFR at stop of CP 130±30.9 130.3±24.7
Median 135.9 Median 131.1
Range 82–164 Range 93–178
GFR at start of CsA 136.3±19.0 p<0.0001
Median 136.5
Range 97–186
GFR at latest follow-up 114.5±14.5 126.4±19.8 p=0.1
Median 114.2 Median 124.6
Range 89–135 Range 92–156
Pediatr Nephrol (2008) 23:581–586 583and arteriolar hyalinosis. However, a review of the literature
demonstrates that it is difficult to predict the influence of
CsA on long-term renal function in patients with MCNS.
Some authors did not find a significant reduction in renal
function under CsA therapy in nephrotic children [4, 8] and
only minor changes in renal histology without progression
of CsA tubulointerstitial lesions [14, 21]. Others empha-
sised reduced GFR [5, 12], reduced renal plasma flow [22]
or progression of tubulointerstitial lesions histologically
[11, 23] in patients with NS and CsA therapy. Histology
progression could not be associated with decrease in renal
function [11, 23] or duration of CsA therapy [7]. Myers et
al. [24] postulated that in case of striped interstitial fibrosis,
some nephrons undergo atrophy while their function could
be compensated for by unaffected nephrons. This may
mask nephrotoxicity by measurements of normal GFR. In
summary, a clear proven association between impaired
renal function and long-term CsA therapy in patients with
MCNS could not be found. But hints permit the question
regarding the safety of long-term CsA therapy in children
with a benign renal disease.
Comparison of results of this study with established
opinions (e.g. [8, 12, 23]) is difficult:
1. Most studies mix different aetiological entities with
different potential to progress to chronic renal failure
(MCNS vs. SRNS and FSGS; [4, 7, 13, 16, 21, 22]).
The impairment of renal function in patients with FSGS
and other types of SRNS cannot reliably be distin-
guished from CsA nephrotoxicity, as those entities have
a high risk for chronic renal failure on their own.
2. In most studies, the follow-up period is restricted to 2–
3 years; in single studies up to 5 years. In this study, at
least ten patients underwent long-term CsA therapy
> 5 years. No other study investigated patients with
such a long treatment period [5–8, 11–14, 23].
Neuhaus et al. and Ganesan et al. [8, 23] evaluated
patients with MCNS only and an extended follow-up time
of 5 years. They evaluated nine patients, with one being
identified with FSGS as the underlying disease in the
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Fig. 3 Development of glomerular filtration rate (GFR) of patients
without cyclosporin A (CsA) therapy (n=15)
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Fig. 2 Boxplot demonstrating
the development of glomerular
filtration rate (GFR) in patients
on cyclosporin A (CsA) therapy
(n=20)
584 Pediatr Nephrol (2008) 23:581–586follow-upbiopsy.AllpatientsreceivedCsAwithhighertrough
levelsandhigherCsAdosage(level:meanof220ng/ml,range
141–270 ng/ml, CsA dosage 126±29 mg/m
2 per day) than
accepted for our study group. The method for CsA level
measurements was a polyclonal assay resulting in higher
levels compared with monoclonal assays. Nevertheless, the
CsA levels and dosage were still higher than in our study
group. CsA toxicity was proven in 3/9 patients histologically.
Ganesan et al. [23] found histological signs for CsA toxicity
in 79% and renal insufficiency with a GFR < 80 in 4/19
patients without correlation to histological changes. Again,
that study mixed patients with steroid-resistant and steroid-
responsive NS, not distinguishing between the different
clinical entities.
In our study, only patients with histologically proven
MCNS were evaluated for long-term renal function under
CsA therapy. Patients qualified for the study only after a
minimum treatment duration of 2 years. The follow-up
period extended over a mean of 5.4 years, with ten patients
who had been treated between 5 and 11 years. At least in
half of the patients with long-term CsA therapy > 5 years,
CsA toxicity was excluded by biopsy. Also in our study
group, the GFR of patients with CsA therapy remained
within the normal range, with a drop within the first
12 months (mean drop 11.8%) and remaining stable
thereafter, with a mean GFR of 115±16 ml/min per
1.73 m
2. No patient progressed to chronic renal failure,
even after therapy duration of more than 10 years. Hulton et
al. [5, 12] showed comparable results for patients with CsA
therapy, with an initial drop in GFR and a constant renal
function afterwards. But the study is restricted to a short
follow-up of 2 years in four patients only. In our study, a
significant reincrease in GFR after therapy cessation was
not found. In general, these patients showed excellent renal
function in the long-term follow-up (mean 123 ml/min per
1.73 m
2). In contrast, patients in Hulton et al.’s studies
showed a worse GFR of 93 that reincreased back to a GFR
> 100 ml/min per 1.73 m
2 after CsA had been stopped.
Interestingly, in our control group of patients without CsA
therapy, an initial drop in GFR was also found. Those
patients showed a mean drop in GFR of about 5% within the
12 weeks of CP therapy, and GFR even dropped about 8%
until the latest follow-up. Probably, the observed decrease in
GFR in patients with CsA therapy cannot only be attributed
to the hitherto described nephrotoxic effect of CsA.
Hulton et al. [12] mentioned the potential increase of
GFR caused by the mineralocorticoid effect of concomitant
steroid medication. One could speculate that the cessation
of steroids might lead to a physiological drop in GFR.
Additionally, a possible but not proven interpretation
should be discussed: Part of the GFR reduction may be
attributable to normalisation of hyperfiltration in nephrotic
children during the first months after initiation of immuno-
suppressive therapy. In patients with relapsing nephrotic
syndrome, long-term immunosuppressive drugs (e.g. cyclo-
phosphamide, CsA, chlorambucil) are initiated after urine
start CP stop CP latest follow up
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Fig. 4 Boxplot demonstrating
the development of glomerular
filtration rate (GFR) in patients
without cyclosporin A (CsA)
therapy (n=15)
Pediatr Nephrol (2008) 23:581–586 585remission has been achieved; complete remission of serum
albumin normally is not awaited.
Relapse-associatedhypoproteinemiaandhypoalbuminemia
lead to oedema and an increase in GFR. This is explained by
the decrease of the colloid osmotic pressure in the glomerular
capillary. Reduced total serum protein leads to decreased
colloid osmotic pressure and consequently to increased GFR
[15]. Normalisation of the increased filtration extends over
weeks and leads to a decrease in GFR physiologically. This
phenomenon may explain the drop in GFR, even in patients
without nephrotoxic treatment.
In summary, this study offers long-term follow-up of 20
patients with proven SSNS treated with CsA for a median
of 5 years. Initially, the patients showed a drop in GFR but
remained stable afterwards. None developed chronic renal
failure. Nevertheless, the generalisation of these results are
limited, as the study was retrospective, and only 5/20
patients underwent renal biopsy under long-term nephro-
toxic treatment. It is questionable whether a prospective
study to evaluate the outcome of long-term CsA therapy in
children with MCNS is reasonable in the future. Newer,
nonnephrotoxic drugs, e.g. mycophenolate mofetil (MMF)
are of concern and need to be evaluated for efficacy and
safety in the treatment of SDNS and FRNS. However, our
analysis demonstrates that even long-term therapy with
CsA for more than 5 years in children with MCNS is safe
and does not impair renal function.
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